Celularity Divests Biomaterials Business for up to $30M

Celularity Inc. announced a Letter to Shareholders detailing strategic shifts, including the out-licensing of its biomaterials business to NexGel, Inc. for up to $30 million, which also eliminated nearly $13 million in liabilities. This move streamlines operations and refocuses resources on core placental-derived cellular therapy programs, particularly cenplacel-L, for longevity and age-related diseases. The company expects cenplacel-L revenue growth in 2026, driven by physician adoption in Florida, and has appointed Rick Gonzalez as Chief Commercial Officer to lead commercial expansion, while acknowledging a challenging capital environment.